Isofol Medical Begins Clinical Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB ( (SE:ISOFOL) ) has issued an update.

Isofol Medical AB has commenced a clinical phase Ib/II study of arfolitixorin, a potential new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of a standard 5-FU-based therapy. This milestone marks a significant step towards bringing arfolitixorin to market, with expectations of improved treatment outcomes for patients with advanced cancers.

More about Isofol Medical AB

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for various solid tumors, particularly in colorectal cancer, which is the third most common cancer worldwide. Isofol Medical AB is publicly traded on Nasdaq Stockholm.

YTD Price Performance: -15.76%

Technical Sentiment Signal: Buy

Current Market Cap: €27.86M

For detailed information about ISOFOL stock, go to TipRanks’ Stock Analysis page.